At the time of writing, Monte Rosa Therapeutics Inc [GLUE] stock is trading at $24.28, down -4.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GLUE shares have gain 58.59% over the last week, with a monthly amount glided 42.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monte Rosa Therapeutics Inc [NASDAQ: GLUE] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $11 from $14. Previously, Wedbush started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $11. On January 03, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $18 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $22 on October 13, 2022. Jefferies initiated its recommendation with a Buy and recommended $20 as its price target on August 15, 2022. Credit Suisse started tracking with a Neutral rating for this stock on April 28, 2022, and assigned it a price target of $19. In a note dated February 10, 2022, Wells Fargo initiated an Equal Weight rating and provided a target price of $19 on this stock.
For the past year, the stock price of Monte Rosa Therapeutics Inc fluctuated between $3.50 and $25.77. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Monte Rosa Therapeutics Inc [NASDAQ: GLUE] shares were valued at $24.28 at the most recent close of the market. An investor can expect a potential return of 23.56% based on the average GLUE price forecast.
Analyzing the GLUE fundamentals
According to Monte Rosa Therapeutics Inc [NASDAQ:GLUE], the company’s sales were 181.54M for trailing twelve months, which represents an 38.54% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.08 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Monte Rosa Therapeutics Inc [NASDAQ:GLUE] has a current ratio of 6.54. Also, the Quick Ratio is 6.54, while the Cash Ratio stands at 3.39. Considering the valuation of this stock, the price to sales ratio is 9.08, the price to book ratio is 6.10 and price to earnings (TTM) ratio is 79.50.
Transactions by insiders
Recent insider trading involved Warmuth Markus, President & CEO, that happened on Jan 07 ’26 when 5466.0 shares were sold. Officer, Warmuth Markus completed a deal on Jan 07 ’26 to buy 5466.0 shares. Meanwhile, Chief Business & Legal Officer Nickson Philip sold 3155.0 shares on Jan 05 ’26.
